Effect of Tafoxiparin to Treat Primary Slow Progress of Labor Including Prolonged Latent Phase and Labor Arrest

• Status: Completed
• Trial end date: 2019-05-01
• Target enrollment: 0
• Participant gender: Female

Summary

The study will be designed as a double-blind, placebo-controlled, parallel-group, dose-finding study with one group treated with placebo and three groups treated with tafoxiparin in three different infusion concentration levels, respectively. The intravenous infusion will be initiated by a pre-defined bolus dose infusion.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Dilafor AB
• Treatments: Oxytocin

Criteria

Inclusion Criteria:

1. Pregnant women of ≥18 to ≤45 years of age

2. Nulliparous

3. Gestational age > 36 weeks + 6 days confirmed by ultrasound

4. Experience slow progress of labor including prolonged latent phase and labor arrest (according to the respective definitions) etc

Exclusion Criteria:

1. Subjects with secondary slow progress or secondary labor arrest

2. BMI≥35 during first trimester of pregnancy

3. Breech presentation or other abnormal presentations etc